Tilray | TRLY - Assets



Tilray reported $4.19B in Assets for its fiscal quarter ending in November of 2024.


Assets Change Date
Acasti Pharma USD 69.8M 8.58M Jun/2025
Alaunos Therapeutics USD 2.76M 795K Dec/2024
Aurora Cannabis CAD 837.84M 28.68M Jun/2025
Avita Medical AUD 79.71M 8.12M Dec/2024
Canopy Growth CAD 904.67M 259.55M Jun/2025
Cronos Group USD 1.18B 21.4M Jun/2025
Dianthus Therapeutics USD 326.08M 47.93M Jun/2025
Divis Laboratories Ltd 169.32B 13.46B Mar/2025
Ionis Pharmaceuticals USD 2.99B 172.18M Jun/2025
IQVIA Holdings USD 28.63B 1.31B Jun/2025
Knight Therapeutics CAD 962.29M 16.93M Sep/2024
Moderna USD 12.01B 694M Jun/2025
Organigram Holdings CAD 564.62M 85.41M Jun/2025
Organon & Co USD 13.5B 344M Jun/2025
Revvity USD 12.36B 2.06M Jun/2025
Tectonic Therapeutic USD 295.31M 142.4M Jun/2025
Tilray USD 4.19B 70.11M Nov/2024
Viatris USD 38.41B 63.4M Jun/2025
Xeris Pharmaceuticals USD 334.69M 11.63M Jun/2025